[go: up one dir, main page]

SU306669A1 - Erythromycin purification method - Google Patents

Erythromycin purification method

Info

Publication number
SU306669A1
SU306669A1 SU6901352764A SU1352764A SU306669A1 SU 306669 A1 SU306669 A1 SU 306669A1 SU 6901352764 A SU6901352764 A SU 6901352764A SU 1352764 A SU1352764 A SU 1352764A SU 306669 A1 SU306669 A1 SU 306669A1
Authority
SU
USSR - Soviet Union
Prior art keywords
erythromycin
purification method
precipitate
buffer extract
purification
Prior art date
Application number
SU6901352764A
Other languages
Russian (ru)
Inventor
М.Г. Костарева
М.И. Вяткина
Original Assignee
Kostareva M G
Vyatkina M I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kostareva M G, Vyatkina M I filed Critical Kostareva M G
Priority to SU6901352764A priority Critical patent/SU306669A1/en
Application granted granted Critical
Publication of SU306669A1 publication Critical patent/SU306669A1/en

Links

Landscapes

  • Saccharide Compounds (AREA)

Description

Изобретение относитс  к медицине, а (имеШГо к методам получени  антибиотиков; и касаетс  способов очистки эритромицин аThis invention relates to medicine as well (specifically to methods for producing antibiotics; and concerns methods for cleaning erythromycin a

Известен способ очистки эритроми- к цина путем обработки буферного экстракта canbtok Указанный способ, предусматривакицнй использование в качестве соли хлорцстый натрий, не позвол ет получить препарат достаточно высо- jp кой активности и с удовлетворительным качеством.The known method of purification of erythromycin to cin by treating the canbtok buffer extract. This method, involving the use of sodium chloride as a salt, does not allow obtaining the preparation with sufficiently high jp activity and with satisfactory quality.

Цель изобретени  - повышение качества очистки эритромицина. Дл  этого к буферному экстракту добавл ют суль- 55 фат кали , осадок отдел ют, суспендируют в органическом растворителе, например бутилацетате, и осаждают эритромицин-основание подщелачиванием до рнThe purpose of the invention is to improve the quality of erythromycin purification. For this, potassium sulfate is added to the buffer extract, the precipitate is separated, suspended in an organic solvent, for example butyl acetate, and the erythromycin base is precipitated by alkalinization to pH

около 6,5.20about 6.5.20

Пример. К 320 мл буферного экстракта , содержащего 16 мл бутиладетата, с активностью 41000 ед/мп добавл ют сернокислый калий и после перемешивани  в течение 1 ч. отфильтровывают 25 выпавший осадок сульфата эритромицина..Example. Potassium sulphate is added to 320 ml of buffer extract containing 16 ml of butiladetate, with an activity of 41,000 units / mp, and after stirring for 1 hour, 25 erythromycin sulfate precipitate is filtered off.

.Этот осадок суспендируют в 200 ьш бутилацетата и затем расвор ют в 450 мл холодной дистиллированной воды. Водный раствор промывают 2 раза по 15 мл петролейного эфира и осаждают основание эритромицина добавлением водного раствора аммиака до рК 6,-5 при температуре 4-6°С.После нагревани  до 50 С отфил.тровывают осадок антибиотика, высушивают и получают 12,2 г препарата (84% от содержани  в буферном экстракте ) с активностью 920 ед/мг.This precipitate is suspended in 200% butyl acetate and then dissolved in 450 ml of cold distilled water. The aqueous solution is washed with 2 times 15 ml of petroleum ether and the erythromycin base is precipitated by adding an aqueous solution of ammonia to pK 6, -5 at 4-6 ° C. After heating to 50 ° C, the precipitate of the antibiotic is dried, and 12.2 g are obtained drug (84% of the content in the buffer extract) with an activity of 920 units / mg.

Claims (1)

Формула изобретени Invention Formula Способ очистки эритромицина путем обработки буферного экстракта солью, отличающийс  тем, что, с целью повъвиени  качества целевого продукта, к буферному экстракту добавл ют сульфат калич, осадок отдел ют , суспендируют в органическом . растворителе, например бутилацетате, и эритромицин-основание осаждают подщелачиванием до рН около 6,5.The method of purification of erythromycin by treating the buffer extract with salt, characterized in that, in order to increase the quality of the target product, kalic sulfate is added to the buffer extract, the precipitate is separated, suspended in organic. a solvent, such as butyl acetate, and an erythromycin base are precipitated by alkalinization to a pH of about 6.5.
SU6901352764A 1969-06-30 1969-06-30 Erythromycin purification method SU306669A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU6901352764A SU306669A1 (en) 1969-06-30 1969-06-30 Erythromycin purification method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU6901352764A SU306669A1 (en) 1969-06-30 1969-06-30 Erythromycin purification method

Publications (1)

Publication Number Publication Date
SU306669A1 true SU306669A1 (en) 1977-10-25

Family

ID=20446891

Family Applications (1)

Application Number Title Priority Date Filing Date
SU6901352764A SU306669A1 (en) 1969-06-30 1969-06-30 Erythromycin purification method

Country Status (1)

Country Link
SU (1) SU306669A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266905A4 (en) * 2000-03-22 2003-05-07 Chugai Pharmaceutical Co Ltd Process for producing purified erythromycin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266905A4 (en) * 2000-03-22 2003-05-07 Chugai Pharmaceutical Co Ltd Process for producing purified erythromycin
US6767998B2 (en) 2000-03-22 2004-07-27 Chugai Seiyaku Kabushiki Kaisha Method for preparing purified erythromycin

Similar Documents

Publication Publication Date Title
KR900011789A (en) New heparin derivatives and preparation methods thereof
GB1438188A (en) Gentamicin derivatives and a process for the preparation thereof
SU845789A3 (en) Method of preparing d-7-/alpha-(4-oxy-6-methylnicotineamido)-alpha-(4-oxyphenyl)-acetamido/-3-(1-methyltetrazol-5-yl) thiomethyl-3-cephem-4-carboxylic acid
SU306669A1 (en) Erythromycin purification method
GB1426266A (en) Cephradine derivative
EP0259789B1 (en) Metal complexes of n-methyl-11-aza-10-deoxo-10-dihydro-erythromycin a or 11-aza-10-deoxo-10-dihydroerythromycin a, method for the manufacture thereof and their use in the manufacture of pharmaceuticals
US3822256A (en) Crystalline monohydrates of sodium and potassium cephalexin
US3862186A (en) Process for the production of cephalexin monohydrate
US2756226A (en) Acid-stable penicillins
JPS6052719B2 (en) Novel production method for 3',4'-dideoxykanamycin B
US2650216A (en) Crystalline naphthalene sulfonate salts of streptomycin and dihydrostreptomycin
SU700518A1 (en) Method of preparing nw-oxide of 1-nitro-9-(dialkylaminoalkylamine)-acridine
US3937694A (en) Process for the recovery of zinc bacitracin free from zinc hydroxide
GB1296333A (en)
CH525860A (en) 2-alkanoyl-amido-2-desoxyglucosides %saf65&5089
US2357172A (en) Mono-glycosides of 2-methyl-1,4-naphthohydroquinone
SU437762A1 (en) Method for preparing 3-phenylisopropylsidnonimine hydrochloride (sydnophene)
SU62069A1 (en) The method of separation of the double silver salts of thiosulfuric acid from aqueous solutions
PL85039B1 (en) Method for the preparation of sodium salt of α-ftminobenzylopeiiicylmy
SU70496A1 (en) The method of purification of N'-2 '(4', 6'-ditetilpyrididyl) -N4-acylsulfonyl
ES394777A1 (en) Procedure for isolating and purifying 6 - alpha - desoxy - 5 - hydroxytetracicline. (Machine-translation by Google Translate, not legally binding)
SU792835A1 (en) Process for producing o-iodobenzoic acids or their derivatives marked with iodine radioisotopes
JPH0665254A (en) Ceforanide derivative
US2737514A (en) Salts of substituted pteridines and method of preparing the same
US3941773A (en) Form II ampicillin